EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSHHUG00000039101
Gene Symbol: ATP1A1
1 Cross references
152 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSHHUG00000014164
Gene Symbol: ATP1A2
1 Cross references
199 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2a

Ensembl ID : ENSHHUG00000048616
Gene Symbol: ATP1A2A
1 Cross references
199 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSHHUG00000025836
Gene Symbol: ATP1A3
1 Cross references
135 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSHHUG00000003124
Gene Symbol: ATP1B1
1 Cross references
219 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSHHUG00000006900
Gene Symbol: ATP1B1
1 Cross references
224 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSHHUG00000038938
Gene Symbol: ATP1B1
1 Cross references
224 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1b

Ensembl ID : ENSHHUG00000019049
Gene Symbol: ATP1B1B
1 Cross references
219 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSHHUG00000018180
Gene Symbol: ATP1B2B
1 Cross references
198 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSHHUG00000051492
Gene Symbol: ATP1B2B
1 Cross references
197 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSHHUG00000031755
Gene Symbol: ATP1B3A
1 Cross references
230 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSHHUG00000052564
Gene Symbol: ATP1B3A
1 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).